$KOD News

Last published 1h ago

1h agoKODKodiak Sciences to Present at Three Upcoming Investor ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and...
1mo agoKODKodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
1mo agoKODKODIAK CONFERENCE CALL - KODIAK SCIENCES INCEarnings Call TranscriptsThank you for standing by and welcome to Cardiac Sciences Daybreak Webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask
1mo agoKODZenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
1mo agoKODKodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular DegenerationPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
3mo agoKODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsPR NewswirePALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to
3mo agoKODKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026PR NewswireKodiak Sciences Inc. (Nasdaq: KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting...
5mo agoKODKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferencePR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
6mo agoUBER LCID KOD WFG+7TechCrunch Mobility: Lime’s IPO gambleTechCrunch
6mo agoKODKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026....
6mo agoKODKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
7mo agoKODKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended...
7mo agoKODKodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over ShamPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...
9mo agoKODFinal APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
10mo agoKODKodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferencePR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
10mo agoKODKodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
10mo agoKODKodiak Sciences Announces Pricing of Upsized Public Offering of Common StockPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
11mo agoKODKodiak Sciences Announces Proposed Public Offering of Common StockPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
12mo agoKODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025....
12mo agoKODKodiak Sciences to Present at Upcoming Investor ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
1y agoKODFollow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
1y agoKODNew data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
1y agoKODKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
1y agoKODHarbour BioMed Reports 2025 Interim ResultsPR NewswireHarbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
1y agoKODKodiak Sciences to Present at American Chemical Society Fall 2025PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
1y agoKODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our...
1y agoKODKodiak Sciences to Host Investor R&D Day on July 16, 2025PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing...
1y agoKODKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation SocietyPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
1y agoKODKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferencePR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
1y agoKODKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In...
1y agoKODKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular DiseasesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
1y agoKODKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended...
1y agoKODKodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic RetinopathyPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in...
1y agoKODKodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
1y agoKODKodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare ConferencePR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
1y agoKODNona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic DiseasesPR NewswireNona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and...
1y agoKODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third...
2y agoKODKodiak Sciences to Participate in Upcoming Investor ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences to Present at Innovate Retina 2024PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern TimePR NewswireKodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be...
2y agoKODKodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York CityPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical ...
2y agoKODKodiak Sciences to Present at Upcoming Investor and Clinical ConferencesPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to...
2y agoKODKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences Inc. (KOD) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoKODKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter and year ended December 31, 2023. "We...
2y agoKODKodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024PR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
2y agoKODKodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual MeetingPR NewswireKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...